Online inquiry

IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13374MR)

This product GTTS-WQ13374MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LRRC15 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001135057.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 131578
UniProt ID Q8TF66
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LRRC15, PR-1498487(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13374MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4959MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA c2G4-N
GTTS-WQ15989MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ6815MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ8759MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IBI-101
GTTS-WQ11795MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ15331MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
GTTS-WQ8983MR IVTScrip™ mRNA-Anti-IL22, ILV-094(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ILV-094
GTTS-WQ9412MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Iomab-B
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW